The Drug Delivery to the Lungs conference organizing committee and the British Thoracic Society have both announced that they will cut ties with inhalation CDMO Vectura following the company's acquisition by tobacco company Philip Morris International. Vectura announced in May 2021 that it would be acquired by the Carlyle Group; however, the company withdrew its … [Read more...] about DDL, BTS announce that they will cut ties with Vectura following PMI acquisition
Products and Services
Intravacc to offer intranasal vaccine contract development services
Dutch vaccine developer Intravacc has announced that it will continue to develop its pipeline of intranasal vaccines while adding a contract development and manufacturing business. The company said that it will offer GMP manufacturing for clinical trials in addition to R&D services and expects to take on one or two contract projects per year. Intravacc's pipeline … [Read more...] about Intravacc to offer intranasal vaccine contract development services
Adherium’s next generation Hailie inhaler sensor gets 510(k) clearance
According to Adherium, the company has received 510(k) clearance from the FDA for its next generation Hailie inhaler sensor. The new version of the Hailie sensor, which is meant to be used with the Symbicort MDI, includes the ability to capture clinical data in addition to inhaler usage data. Adherium says that the additional capability for monitoring asthma and COPD … [Read more...] about Adherium’s next generation Hailie inhaler sensor gets 510(k) clearance
POC study demonstrates feasibility of using Nanoform’s nanoforming technology for potential intranasal formulation of CDNF
Nanoform Finland and Herantis Pharma say that they have successfully demonstrated the feasibility of using Nanoform's nanoparticle technology for a potential intranasal formulation of Herantis's cerebral dopamine neurotrophic factor (CDNF) for the treatment of Parkinson's disease, with the protein remaining stable and active following processing. The two companies … [Read more...] about POC study demonstrates feasibility of using Nanoform’s nanoforming technology for potential intranasal formulation of CDNF
Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx's SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19. The project is supported by Swiss life sciences investment company ADYA Consulting. According to the … [Read more...] about Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
Cellics partners with HCmed on delivery of inhaled nanosponges
Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and the company expects to advance its CTI-005 RBC nanosponge into clinical development for the … [Read more...] about Cellics partners with HCmed on delivery of inhaled nanosponges
Aptar Pharma gets option to acquire Pharmaxis’s Orbital DPI
Aptar Pharma will have 12 months to decide whether to exercise an exclusive option to acquire worldwide rights to Pharmaxis's high payload Orbital dry powder inhaler under a new agreement, the company said. The Orbital DPI, which can deliver up to 400 mg of powder in divided doses, was designed for delivery of Pharmaxis's Bronchitol inhaled mannitol, and Pharmaxis … [Read more...] about Aptar Pharma gets option to acquire Pharmaxis’s Orbital DPI
FDA indicates that Merxin’s MRX004 SMI could be used for generics of Spiriva Respimat
According to a LinkedIn post by generic device maker Merxin, the FDA has indicated that Merxin's MRX004 soft mist inhaler is suitable for an ANDA submission for a generic version of Boehringer Ingelheim's Spiriva Respimat tiotropium bromide SMI. Merxin recently announced that it would sponsor doctoral research at the University of Hertfordshire to support development … [Read more...] about FDA indicates that Merxin’s MRX004 SMI could be used for generics of Spiriva Respimat
Berry Global to build new R&D and manufacturing facility in India
Berry Global has announced that it will construct a new facility in Bangalore, India that will serve as an R&D center and will add manufacturing capacity for devices, including nasal spray pumps and inhalers, to meet demand in South Asia. Berry already has one manufacturing facility in Bangalore. Berry Global Chairman and CEO Tom Salmon commented, "Investing in … [Read more...] about Berry Global to build new R&D and manufacturing facility in India
H&T Presspart acquires Novelex
H&T Presspart has acquired Swiss device maker Novelex (formerly Forteq Nidau), the company said, and all Novelex employees will be absorbed into H&T Presspart. The company acquired Novelex from Liberta Partners, which had acquired Forteq Nidau in November 2020. Two partners from Liberta Partners, Florian Korp and Peter Franke, commented, "H&T … [Read more...] about H&T Presspart acquires Novelex